N-of-One inked an agreement with Belgian personalized medicine firm OncoDNA under which it will provide clinical interpretation for all of OncoDNA's next-generation sequencing (NGS) and other molecular tests for patients throughout Europe, the Middle East, and other parts of the world.
OncoDNA provides tumor profiling services designed to help medical doctors choose treatments and monitor tumor evolution. N-of-One's clinical interpretation, OncoDNA says, can provide biological and clinical knowledge and insights related to a tumor's mutation profile, linking this knowledge to therapeutic strategies including clinical trials. In a statement, Jean-Pol Detiffe, OncoDNA's CEO, added that, in addition to clinical interpretation, N-of-One was tapped for its ability to integrate different types of molecular test results into a single report rapidly.
“OncoDNA's industry-leading, molecular diagnostic solutions, coupled with N-of-One's deep expertise in clinical interpretation in oncology, will enable broader patient access worldwide to personalized cancer treatment in a scalable, cost-effective manner,” commented N-of-One's CEO Chris Cournoyer.
Back in March, N-of-One teamed up with genomics visualization and analysis software developer BioDiscovery to provide integrated genomic analysis interpretation solutions. It inked a similar deal with Appistry in February to provide genetic sequencing data analysis and molecular interpretation services.
